Buscar
Organon & Co
OGNAñadir a la lista de seguimiento
13.475USD
+0.025+0.19%
Cierre 06/24, 16:00（ET）Cotizaciones retrasadas 15 min
3.50BCap. mercado
14.27P/E TTM
Más Datos de Organon & Co Compañía
Organon & Co. is a global healthcare company. The Company is engaged in developing and delivering health solutions through a portfolio of prescription therapies and medical devices within women's health, biosimilars and a franchise of established medicines across a range of therapeutic areas. It has a portfolio of approximately 70 medicines and products across a range of therapeutic areas. It has a portfolio of contraception and fertility brands, including Nexplanon, NuvaRing, and Follistim AQ. Its Biosimilars portfolio spans across immunology and oncology treatments. It also has a portfolio of established brands, including brands in cardiovascular, dermatology and non-opioid pain management. It sells these products through various channels, including drug wholesalers and retailers, hospitals, government agencies and managed health care providers, such as pharmacy benefit managers and other institutions.
Información de Organon & Co
Símbolo de cotizaciónOGN
Nombre de la empresaOrganon & Co
Fecha de salida a bolsaMay 14, 2021
Director ejecutivoMorrissey (Joseph T)
Número de empleados10000
Tipo de seguridadOrdinary Share
Fin del año fiscalMay 14
Dirección30 Hudson Street
CiudadJERSEY CITY
Bolsa de valoresNASDAQ OMX NASDAQ Basic NYSE
PaísUnited States of America
Código postal07302
Teléfono15514306000
Sitio Webhttps://www.organon.com/
Símbolo de cotizaciónOGN
Fecha de salida a bolsaMay 14, 2021
Director ejecutivoMorrissey (Joseph T)
Ejecutivos de Organon & Co
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Matthew M. (Matt) Walsh
Mr. Matthew M. (Matt) Walsh
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
212.75K
--
Ms. Rachel A. Stahler
Ms. Rachel A. Stahler
Executive Vice President, Chief Digital and Growth Officer
Executive Vice President, Chief Digital and Growth Officer
116.52K
+0.36%
Mr. Aaron Falcione
Mr. Aaron Falcione
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
101.67K
+4.83%
Mr. Kirke Weaver
Mr. Kirke Weaver
Executive Vice President, General Counsel, Corporate Secretary
Executive Vice President, General Counsel, Corporate Secretary
92.70K
+0.06%
Mr. Vittorio Nisita
Mr. Vittorio Nisita
Executive Vice President, Head of Enterprise Services & Solutions
Executive Vice President, Head of Enterprise Services & Solutions
70.86K
+5.78%
Ms. Rochelle B. (Shelly) Lazarus
Ms. Rochelle B. (Shelly) Lazarus
Independent Director
Independent Director
633.00
--
Ms. Shalini Sharp
Ms. Shalini Sharp
Independent Director
Independent Director
2.00
--
Mr. Robert A. (Bob) Essner
Mr. Robert A. (Bob) Essner
Lead Independent Director
Lead Independent Director
--
--
Ms. Cynthia M. Patton
Ms. Cynthia M. Patton
Independent Director
Independent Director
--
--
Ms. Grace M. Puma Whiteford
Ms. Grace M. Puma Whiteford
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Matthew M. (Matt) Walsh
Mr. Matthew M. (Matt) Walsh
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
212.75K
--
Ms. Rachel A. Stahler
Ms. Rachel A. Stahler
Executive Vice President, Chief Digital and Growth Officer
Executive Vice President, Chief Digital and Growth Officer
116.52K
+0.36%
Mr. Aaron Falcione
Mr. Aaron Falcione
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
101.67K
+4.83%
Mr. Kirke Weaver
Mr. Kirke Weaver
Executive Vice President, General Counsel, Corporate Secretary
Executive Vice President, General Counsel, Corporate Secretary
92.70K
+0.06%
Mr. Vittorio Nisita
Mr. Vittorio Nisita
Executive Vice President, Head of Enterprise Services & Solutions
Executive Vice President, Head of Enterprise Services & Solutions
70.86K
+5.78%
Ms. Rochelle B. (Shelly) Lazarus
Ms. Rochelle B. (Shelly) Lazarus
Independent Director
Independent Director
633.00
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Organon & Co?
Los cinco principales accionistas de Organon & Co son: Mr. Matthew M. (Matt) Walsh
¿Cuántas instituciones poseen acciones de Organon & Co (OGN)?
A fecha de 2026Q1, 1398 instituciones poseen acciones de Organon & Co, con un valor de mercado combinado de aproximadamente 239.27M, lo que representa el 91.12% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -3985201.00.
¿Cuál es la mayor fuente de ganancias de Organon & Co?
El 2026Q1, el segmento empresarial Women’s Health generó la ganancia más alta para Organon & Co, ascendiendo a 1.75B y representando el 28.19% de la ganancia total.
